Xcell 20biosciences 20  20ucsf 20  20ctc 20and 20wbc 20study page 06
Xcell 20biosciences

Xcell Biosciences

Xcell has developed a technology to capture and culture cancer and other primary cells from blood and solid tissue for use as a new research and discovery tool.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Francisco, CA, US
  • Currency USD
  • Founded June 2012
  • Employees 5
  • Website xcellbio.com

Company Summary

Xcell Biosciences is democratizing primary cell culture through an integrated set of products combining specialized substrates, media, and protocols, with a proprietary growth chamber as a new research and drug discovery technology for cancer and other primary cell types. As a key application, this technology for the first time provides researchers and clinicians with an abundant source of patient-derived cancer cells, directly from patient blood


  • Dea13d8b 0619 4e12 8356 3cacff2ec782
    Chief Scientific Officer

    James is an experienced cancer biologist and imaging expert in high resolution fluorescence microscopy – most recently a research scientist at Lawrence Berkeley National Lab. Prior to LBL, James was a researcher at Harvard Medical School, where he characterized circulating tumor cells (CTCs).

  • 9af80bde d902 4382 a9a5 41f3a462f410
    Chief Executive Officer

    Brian is an experienced business professional educated as a molecular biologists. He formerly worked as a business strategy life sciences consultant at L.E.K. Consulting and in private equity at Strategyn Equity Partners. He was most recently with Novartis Pharma, and has degrees from Purdue University, Keck Graduate Institute of Applied Life Sciences, University of California, Berkeley.

  • B368556c 4eb0 4903 bf2a 3e8ddf285538
    Chief Technology Officer

    The technology’s computer vision algorithms for high content screening applications are under development by Craig Yoshioka, PhD, who has extensive experience in hardware automation and image analysis software development. Craig joins us as a scientist with start-up industry experience and a doctorate from The Scripps Research Institute.


Previous Investors

  • Default avatar
    Steve Blank
    Dac20e57 2e5b 4857 9c4b 2dca09686fb6
    Default avatar
    Jim Hornthal
  • Default avatar
    Wilson Sonsini Goodrich & Rosati